CTI Signs Memorandum with Samsung Medical Center
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization has signed a Memorandum of Understanding (MOU) with Samsung Medical Center (SMC), located in Seoul, South Korea. The purpose of the Memorandum is to affirm both CTI's and SMC's commitment to identifying and developing opportunities for cooperation and collaboration in advancing clinical research in fields such as rare and orphan disease, regenerative medicine, and hematology/oncology. The Memorandum was signed by Patrick J. Earley, CTI's Chief International Business Officer and Ki Woong Sung, Director of Clinical Research Institute at SMC.
"We are thrilled to enter this strategic partnership with Samsung Medical Center," remarks Patrick J. Earley. "Samsung Medical Center is an innovative research site that is committed to bringing life-changing drugs to patients in need, just as CTI is. We have been working throughout the Asia-Pacific region for nearly a decade, and we have many successful collaborations throughout the region with leading academic centers and emerging biotechnology companies. CTI continues to grow steadily in the region, and we look forward to future accomplishments/efficiencies enabled by this partnership."
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
